"A focus may be benign or malignant, with the estimated risk of malignancy differing widely between studies, ranging from 0.6 to 37% 1,2,4-6. At the index study, a focus is commonly assessed as probably benign and short term follow up is recommended (BI-RADS 3). Scattered multiple foci, a focus with long term stability, a decreasing or resolved focus, a focus with 100% persistent delayed kinetics, or a focus with cyst-like features may be considered benign (BI-RADS 2). Conversely, a focus that is new, enlarged, or showing washout kinetics may be viewed as suspicious (BI-RADS 4)."
"A focus in the context of breast MRI using the BI-RADS lexicon refers to a unique enhancing dot that is too small to characterise further morphologically as a mass or nonmass enhancement. Usually, a focus is smaller than 5 mm."
"T1 C+ FS: punctate signal that stands out from the background parenchymal enhancement, usually"
"A focus may be benign or malignant, with the estimated risk of malignancy differing widely between studies, ranging from 0.6 to 37% 1,2,4-6. At the index study, a focus is commonly assessed as probably benign and short term follow up is recommended (BI-RADS 3). Scattered multiple foci, a focus with long term stability, a decreasing or resolved focus, a focus with 100% persistent delayed kinetics, or a focus with cyst-like features may be considered benign (BI-RADS 2). Conversely, a focus that is new, enlarged, or showing washout kinetics may be viewed as suspicious (BI-RADS 4)."
"A focus may be benign or malignant, with the estimated risk of malignancy differing widely between studies, ranging from 0.6 to 37% 1,2,4-6. At the index study, a focus is commonly assessed as probably benign and short term follow up is recommended (BI-RADS 3). Scattered multiple foci, a focus with long term stability, a decreasing or resolved focus, a focus with 100% persistent delayed kinetics, or a focus with cyst-like features may be considered benign (BI-RADS 2). Conversely, a focus that is new, enlarged, or showing washout kinetics may be viewed as suspicious (BI-RADS 4)."
"A focus may be benign or malignant, with the estimated risk of malignancy differing widely between studies, ranging from 0.6 to 37% 1,2,4-6. At the index study, a focus is commonly assessed as probably benign and short term follow up is recommended (BI-RADS 3). Scattered multiple foci, a focus with long term stability, a decreasing or resolved focus, a focus with 100% persistent delayed kinetics, or a focus with cyst-like features may be considered benign (BI-RADS 2). Conversely, a focus that is new, enlarged, or showing washout kinetics may be viewed as suspicious (BI-RADS 4)."
"T1 C-: no corresponding finding; possibly fatty hilum favours a benign process"
"T1 C+ FS: punctate signal that stands out from the background parenchymal enhancement, usually"
"T2: if present, hyperintensity (cyst-like) favours benignity, such as lymph nodes or myxomatous fibroadenomas"
Expected headings
"Radiographic appearance"
"MRI"
"T1 C-: no corresponding finding; possibly fatty hilum favours a benign process"